nct_id: NCT06435429
age: Adults
cancer_center_accrual_goal_upper: 0
curated_on: '2024-05-30'
study_start_date: '2024-08-13'
study_completion_date: null
data_table4: Interventional
drug_list:
  drug:
  - drug_name: 'Drug: Zanidatamab'
  - drug_name: 'Drug: Capecitabine'
  - drug_name: 'Drug: Vinorelbine'
  - drug_name: 'Drug: Trastuzumab'
  - drug_name: 'Drug: Eribulin'
  - drug_name: 'Drug: Gemcitabine'
long_title: A Phase 3, Randomized, Open-label, Multicenter, Controlled Study to Evaluate
  the Efficacy and Safety of Zanidatamab in Combination With Physician's Choice Chemotherapy
  Compared to Trastuzumab in Combination With Physician's Choice Chemotherapy for
  the Treatment of Participants With Metastatic HER2-positive Breast Cancer Who Have
  Progressed on, or Are Intolerant to, Previous Trastuzumab Deruxtecan Treatment
last_updated: '2025-10-28'
management_group_list:
  management_group:
  - is_primary: Y
    management_group_name: Group1
oncology_group_list:
  oncology_group:
  - group_name: Group1
    is_primary: N
phase: PHASE3
principal_investigator: NA
principal_investigator_institution: Jazz Pharmaceuticals
program_area_list:
  program_area:
  - is_primary: Y
    program_area_name: Program1
protocol_id: 0
protocol_ids: []
protocol_no: ''
protocol_target_accrual: 550
protocol_type: INTERVENTIONAL
prior_treatment_requirements:
- 'Participants are eligible to be included in the study only if all of the following
  criteria apply:'
- 1. Is 18 years of age or of the legal adult age per local standard at the time of
  signing the informed consent.
- 2. Has histologically confirmed HER2-positive breast cancer according to ASCO-CAP
  Guidelines as evaluated by a central laboratory
- 3. Participants with unresectable or metastatic HER2 positive breast cancer who
  have progressed on, or are intolerant to, previous T-DXd treatment.
- 4. Has measurable disease per RECIST version 1.1.
- 5. Is eligible to receive one of the chemotherapy options listed in the physician's
  choice of chemotherapy (eribulin, gemcitabine, vinorelbine, or capecitabine).
- 6. Participants with history of treated or clinically inactive CNS metastases are
  eligible as specified in the protocol.
- 7. Has a life expectancy of at least 6 months, in the opinion of the investigator.
- 8. Has adequate hematologic parameters as defined in the protocol.
- 9. Has adequate hepatic function as specified in the protocol.
- "10. Has creatinine clearance \u2265 30 mL/minute as calculated per local institutional\
  \ guidelines."
- "11. Has LVEF \u2265 50% as determined by either echocardiogram or MUGA obtained\
  \ within 4 weeks before the first dose of study intervention."
- 12. Has ECOG performance status of 0 or 1.
- 13. Participant agrees to the following based on sex assigned at birth.
- '1. Male participants:'
- 'Male participants are eligible to participate if they agree to the following during
  the study intervention period and for at least 5 months after the last dose of study
  intervention or the contraception period for the combination chemotherapy of choice
  per local guidance/standard practice, whichever is longer:'
- '* Refrain from donating fresh unwashed semen.'
- '* Use contraception as follows as specified in the protocol'
- '2. Female participants:'
- '* A female participant is eligible to participate if she is not pregnant or breastfeeding,
  and one of the following conditions applies:'
- '* Is a women of nonchildbearing potential OR'
- '* Is a woman of childbearing potential (WOCBP) and using a contraceptive method
  that is highly effective (with a failure rate of \< 1% per year), with low user
  dependency during the study intervention period and for at least 5 months after
  the last dose of study intervention or the contraception period for the combination
  chemotherapy of choice per local guidance/standard practice, whichever is longer.'
- '* A WOCBP must have a negative highly sensitive pregnancy test (urine or serum
  as required by local regulations) within 3 days before the first dose of study intervention.'
- '* Additional requirements for pregnancy testing during and after study intervention
  are provided in the protocol.'
- '* The investigator is responsible for review of medical history, menstrual history,
  and recent sexual activity to decrease the risk for inclusion of a woman with an
  early undetected pregnancy.'
- 14. Is capable of giving signed informed consent, which includes compliance with
  the requirements and restrictions listed in the informed consent form and in the
  protocol.
- 'Participants are excluded from the study if any of the following criteria apply:'
- Medical Conditions
- 1. Has known or suspected leptomeningeal disease.
- 2. Has uncontrolled or significant cardiovascular disease.
- "3. Has toxicity related to prior cancer therapy that has not resolved to \u2264\
  \ Grade 1, with exceptions as stated in the protocol."
- 4. Has uncontrolled infection requiring IV antibiotics, antivirals, or antifungals.
- 5. Has known HIV infection.
- 6. Has active hepatitis B or C infection.
- 7. Has an active SARS-CoV-2 infection. Participants with prior infection that has
  resolved per local institutions' requirements and screening guidance are eligible.
- 8. Has a history of life-threatening hypersensitivity to monoclonal antibodies or
  to recombinant proteins or excipients in the drug formulation of zanidatamab.
- 9. Is unable to receive trastuzumab treatment due to medical contraindications.
- 10. Has any serious underlying medical or psychiatric condition that would impair
  the ability of the participant to receive or tolerate the planned treatment at the
  investigational site.
- 11. Has any condition that would prevent treatment with the physician's choice of
  chemotherapy.
- 12. Has any issue or condition that in the opinion of the investigator would contraindicate
  the participant's participation in the study or confound the results of the study.
- Prior/Concomitant Therapy
- 13. Has a history of prior allogeneic bone marrow, stem cell, or solid organ transplantation.
- 14. Was treated with any local or systemic antineoplastic therapy (including hormonal
  therapies for breast cancer) or any investigational therapy within 4 weeks or 5
  half-lives (whichever is longer) prior to randomization.
- 15. Has a history of trauma or major surgery within 4 weeks prior to randomization.
- Other Exclusions
- 16. Has a known hypersensitivity to any components of the study drugs, including
  chemotherapy.
- 17. Female participants who are breastfeeding or pregnant, and female and male participants
  planning a pregnancy.
short_title: A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab,
  Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants
  With Metastatic HER2-positive Breast Cancer
site_list:
  site: []
sponsor_list:
  sponsor:
  - is_principal_sponsor: Y
    sponsor_name: Jazz Pharmaceuticals
    sponsor_protocol_no: ''
    sponsor_roles: sponsor
staff_list:
  protocol_staff: []
status: open to accrual
summary: The efficacy and safety of zanidatamab in combination with physician's choice
  of chemotherapy compared with trastuzumab in combination with physician's choice
  of chemotherapy will be evaluated for the treatment of participants with metastatic
  HER2-positive breast cancer who have progressed on, or are intolerant to, previous
  T-DXd treatment.
treatment_list:
  step:
  - step_internal_id: 111
    step_code: '1'
    step_type: Registration
    arm:
    - arm_code: Zanidatamab plus physician's choice of chemotherapy
      arm_internal_id: 0
      arm_description: Participants with HER2-positive metastatic breast cancer (mBC)
        who have progressed on, or are intolerant to, previous T-DXd treatment will
        be randomized to receive intravenous infusion of zanidatamab plus physician's
        choice of chemotherapy (eribulin, or vinorelbine, or gemcitabine, or capecitabine).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Zanidatamab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Eribulin'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Vinorelbine'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Gemcitabine'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Capecitabine'
        level_internal_id: 4
        level_suspended: N
    - arm_code: Trastuzumab plus physician's choice of chemotherapy
      arm_internal_id: 1
      arm_description: Participants with HER2-positive metastatic breast cancer (mBC)
        who have progressed on, or are intolerant to, previous T-DXd treatment will
        be randomized to receive intravenous infusion of trastuzumab plus physician's
        choice of chemotherapy (eribulin, or gemcitabine, or vinorelbine, or capecitabine).
      arm_suspended: N
      dose_level:
      - level_code: '0'
        level_description: 'Drug: Trastuzumab'
        level_internal_id: 0
        level_suspended: N
      - level_code: '1'
        level_description: 'Drug: Eribulin'
        level_internal_id: 1
        level_suspended: N
      - level_code: '2'
        level_description: 'Drug: Vinorelbine'
        level_internal_id: 2
        level_suspended: N
      - level_code: '3'
        level_description: 'Drug: Gemcitabine'
        level_internal_id: 3
        level_suspended: N
      - level_code: '4'
        level_description: 'Drug: Capecitabine'
        level_internal_id: 4
        level_suspended: N
    match:
    - and:
      - and:
        - or:
          - clinical:
              oncotree_primary_diagnosis: Breast Neoplasm, NOS
          - clinical:
              oncotree_primary_diagnosis: Invasive Breast Carcinoma
        - clinical:
            age_numerical: '>=18'
            her2_status: Positive
            disease_status:
            - Unresectable
            - Metastatic
      - or:
        - genomic:
            hugo_symbol: ERBB2
            variant_category: Mutation
